Sequential Expansion of Comparative Effectiveness of Anticoagulants



Status:Completed
Conditions:Atrial Fibrillation
Therapuetic Areas:Cardiology / Vascular Diseases
Healthy:No
Age Range:18 - Any
Updated:12/7/2017
Start Date:March 7, 2014
End Date:November 1, 2017

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

Sequential Expansion of Comparative Effectiveness of Oral Anticoagulants: A Cohort Study

This cohort study is the sequential expansion of the comparative effectiveness study of oral
anticoagulants and plans to identify initiators of oral anticoagulants using electronic
claims data from a commercial insurance database to quantify associations between
anticoagulant choice (warfarin and dabigatran) and the occurrence of selected outcomes in
patients with non-valvular atrial fibrillation at risk for stroke.


Inclusion criteria:

- A recorded diagnosis of atrial fibrillation.

- Initiation of anticoagulant medication (dabigatran (or other new oral anticoagulants
as they become available) or warfarin).

- At least 18 years of age on the date of anticoagulant initiation.

- CHA2DS2-VASc score at least 1

Exclusion criteria:

- Patients with missing or ambiguous age or sex information.

- Patients with evidence of valvular disease.

- Patients with less than 12 months enrolment preceding the date of anticoagulant
initiation

- Patients with a dispensing of any oral anticoagulant during the 12 months preceding
the date of anticoagulant initiation

- Patients with a nursing home stay during the 12 months preceding the date of
anticoagulant initiation
We found this trial at
1
site
Brigham and Women's Hosp
75 Francis street
Boston, Massachusetts 02115
(617) 732-5500
Brigham and Women's Hosp Boston’s Brigham and Women’s Hospital (BWH) is an international leader in...
?
mi
from
Boston, MA
Click here to add this to my saved trials